The Best of Canadian Science and Technology
In order for any company to weather the many storms it is likely to encounter as it progresses from inception to maturity, it must not only be blessed … [Read more...] about Denzil Doyle: Canadian Techs Need to Build Stronger Boards
Neptune Technologies (TSXV:NTB) yesterday reported its Q3, 2012 results. The numbers appeared to be a mixed bag; revenue was up by 19% to $5.12 … [Read more...] about Byron Capital’s Douglas Loe says Neptune Technologies is a BUY
In Canada, the shadow of Nortel is large and, seemingly, persistent. The fallen Ottawa tech giant, which once represented 36% of the total value of … [Read more...] about Cantech’s Nick Waddell talks Nortel with Michael Hainsworth of BNN
UPDATE! We've updated the analyst picks for 2013, check out the Top Picks of some of Canada's best tech analysts here. What stocks will you be … [Read more...] about 10 Canadian Tech Stocks to Watch in 2012
On Thursday, Sandvine (TSX:SVC) announced its fiscal 2011 results. Revenue came in at (US) $89.3 million compared to $92.08 in fiscal 2010, and the … [Read more...] about M Partners analyst Ron Shuttleworth: Sandvine Appears to be Plateauing
In an update to clients today, Versant Partners revealed its top picks for 2012. While the list is a diverse one, Versant says its favours stocks that … [Read more...] about Versant Partners Reveals its Top 5 Tech Picks for 2012
After the recession of 2008, infrastructure spending seemed one of the better defensive places to be. Aging pipelines, electrical transmission … [Read more...] about Byron Capital’s Berry says Clearford Industries is a Speculative Buy
When the offer came, it came seemingly out of nowhere. Shares of RuggedCom (TSX:RCM), which had been struggling since the middle part of 2011, leapt … [Read more...] about Byron Capital’s Tom Astle raises Target Price on RuggedCom to $30
Longueuil, Quebec’s Innergex Renewable Energy (TSX:INE), which was founded back in 1990 but IPO'd in 2007, already knows better than most that the … [Read more...] about M Partners John Safrance: Not much upside in Innergex Renewable for 2012
In a recent note to clients, Byron Capital's Healthcare and Biotech Analyst Douglas Loe reiterated his Speculative Buy target on Protox Therapeutics … [Read more...] about Byron Capital’s Douglas Loe: the Market is Undervaluing Protox Therapeutics
